Skip to main content

Advertisement

SpringerLink
Log in

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case–control study and a pooled meta-analysis

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Encouraged by recent studies on the MTHFR 677C>T polymorphism and breast cancer risk that suggested an association of the 677 TT genotype with increased breast cancer susceptibility in premenopausal women, we performed an analysis of the relationship between breast cancer risk and the MTHFR 677C>T polymorphism in 210 premenopausal breast cancer patients and sex- and agematched healthy control subjects. Our data show a trend for a higher MTHFR 677T allele frequency in breast cancer cases (61.9%) than in controls (51.5%, P = 0.082) supporting the results of previous studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Macis D, Maisonneuve P, Johansson H et al (2007) Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case–control study and a pooled meta-analysis. Breast Cancer Res Treat (in press). DOI 10.1007/s10549-006-9491-6

  2. Langsenlehner U, Krippl P, Renner W et al (2003) The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat 81:169–172

    Article  PubMed  CAS  Google Scholar 

  3. Zintzaras E (2006) Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet 69:327–336

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria

    Tanja Langsenlehner

  2. Clinical Institute of Medical and Laboratory Diagnostics, Medical University of Graz, Graz, Austria

    Wilfried Renner

  3. Deparment of Internal Medicine, Division of Rheumatology, Medical University of Graz, Graz, Austria

    Babak Yazdani-Biuki

  4. Department of Internal Medicine, Division of Oncology, Medical University of Graz, Auenbruggerplatz 15, Graz, 8036, Austria

    Uwe Langsenlehner

Authors
  1. Tanja Langsenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wilfried Renner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Babak Yazdani-Biuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uwe Langsenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Langsenlehner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langsenlehner, T., Renner, W., Yazdani-Biuki, B. et al. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case–control study and a pooled meta-analysis. Breast Cancer Res Treat 107, 459–460 (2008). https://doi.org/10.1007/s10549-007-9564-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9564-1

Keywords

Search

Navigation